You are here: Home: Audio Program Guide: BCU 4 | 2006 Audio: BCU 4 | 2006
 
  Go to interview with Stephen E Jones, MD
Go to interview with Kathy D Miller, MD
Go to interview with Charles L Vogel, MD
 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Stephen E Jones, MD
Director, Breast Cancer Research
Charles A Sammons Cancer Center
Baylor University Medical Center
Dallas, Texas
Chair, US Oncology Breast Cancer Research
Medical Director, US Oncology Research
Houston, Texas		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Development of doxorubicin/cyclophosphamide (AC)
Track 3 Adjuvant trials evaluating AC
Track 4 US Oncology trial of docetaxel/cyclophosphamide (TC) versus AC as adjuvant therapy
Track 5 Efficacy and tolerability of TC versus AC
Track 6 Anthracycline-related cardiotoxicity

Track 7 Differences in quality of life for patients receiving TC versus AC
Track 8 Impact of ER status in trial comparing TC versus AC
Track 9 Dose-dense ACArrowpaclitaxel versus docetaxel/doxorubicin/cyclophosphamide (TAC) in patients with ER-positive disease
Track 10 Selection of adjuvant chemotherapy for patients with node-positive disease
Track 11 ECOG-E2197: Phase III randomized study of doxorubicin/docetaxel (AT) versus AC as adjuvant therapy
Track 12 Phase III adjuvant trial of doxorubicin/paclitaxelArrowpaclitaxel versus ACArrowpaclitaxel
Track 13 Evolution of the use of fluoropyrimidines in the adjuvant setting
Track 14 ECOG-E1199: Phase III study of AC followed by different schedules of paclitaxel and docetaxel
Track 15 Prophylactic use of growth factor support with docetaxel
Track 16 Future directions for US Oncology adjuvant trials
Track 17 US Oncology neoadjuvant trial of 5-FU/epirubicin/cyclophosphamide (FEC)Arrowcapecitabine/docetaxel
Track 18 Impact of WINS study results on clinical practice
Track 19 Integration of bevacizumab into the treatment algorithm
Track 20 Tolerability of docetaxel versus paclitaxel
Track 21 Nanoparticle albumin-bound (nab) paclitaxel
     
Kathy D Miller, MD
Sheila D Ward Scholar of Medicine
Associate Professor of Medicine
Department of Hematology/Oncology
Indiana University School of Medicine
Indianapolis, Indiana
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Role of VEGF in normal and tumor cell function
Track 3 Mechanism of action of bevacizumab
Track 4 Role of bevacizumab in decreasing interstitial tumor pressure and increasing vascular permeability
Track 5 Clinical trial of neoadjuvant bevacizumab in patients with inflammatory breast cancer
Track 6 Anti-angiogenic effects of chemotherapeutic agents

Track 7 Utility of basic science to understand clinical observations
Track 8 Biologic rationale for side effects associated with bevacizumab
Track 9 Dosing of bevacizumab in different tumor types
Track 10 Potential role of small molecule tyrosine kinase inhibitors (SMTKIs) in breast cancer
Track 11 Case discussion: Woman with ER/PR/HER2-negative metastatic disease treated with a SMTKI
Track 12 Side effects associated with SMTKIs
Track 13 Early clinical trials of bevacizumab in breast cancer
Track 14 Interpretation of results from the Phase III trial with capecitabine/bevacizumab
Track 15 ECOG-E2100: Paclitaxel with or without bevacizumab as first-line therapy
Track 16 Clinical impact of the ECOG-E2100 trial results
Track 17 Rationale for lack of crossover in ECOG-E2100
Track 18 Potential biologic rationale for benefit of adjuvant bevacizumab
Track 19 Bevacizumab in patients treated previously with adjuvant taxanes
Track 20 Predictors of response to bevacizumab
Audio
Track 21 XCaliBr trial: Capecitabine/bevacizumab as first-line therapy for metastatic disease
Audio
Track 22 Phase II trial evaluating bevacizumab in combination with trastuzumab
Audio
Track 23 Combining bevacizumab with hormonal therapy in patients with ER-positive disease
Audio
Track 24 Potential challenges with bevacizumab in the neoadjuvant setting
Audio
Track 25 Background and design of adjuvant bevacizumab trial
Audio
Track 26 Incidence and pathophysiology of arterial and cardiac events with bevacizumab
Audio
Track 27 Pilot study of adjuvant bevacizumab monotherapy versus bevacizumab with metronomic chemotherapy
Audio
Track 28 Integration of bevacizumab into clinical practice
Audio
Track 29 Utilization of bevacizumab with other chemotherapeutic agents
Audio
Track 30 Societal and economic costs associated with cancer therapy
Audio
     
Charles L Vogel, MD
Medical Director
Cancer Research Network Inc
Plantation, Florida		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Case discussion 1: A 61-year-old woman with metastatic breast cancer to the liver treated with high-dose estrogen therapy
Track 3 Patient interview: Impact of a cancer diagnosis
Track 4 Case discussion 2: A 79-year-old woman with erythematous skin nodules treated with capecitabine
Track 5 Patient interview: Response to and tolerability of capecitabine
Audio
Track 6 Case discussion 3: Woman with prior soft-tissue metastases and a brachial plexopathy treated with capecitabine
Audio
Track 7 Patient interview: Tolerability of capecitabine
Track 8 Benefit of oral administration of capecitabine
Track 9 Impact of cancer diagnosis on life perspective
Track 10 Case discussion 4: Young woman with a prior history of a stem cell transplant
Track 11 Integration of bevacizumab into clinical management strategies
Audio
Track 12 Patient interview: Impact of capecitabine versus other chemotherapeutic agents on quality of life
Audio
Track 13 Impact of cancer diagnosis on children
Audio
Track 14 Case discussion 5: A woman treated with trastuzumab for metastatic breast cancer since 1998
Audio
Track 15 Quality control with HER2 and ER testing
Audio
Track 16 Personal perspective on treating patients with breast cancer
Audio
Track 17 Patient interview: Change in life perspective after a diagnosis of cancer
Audio
Track 18 Sharing a diagnosis of metastatic disease with children
Audio
Track 19 Personal perspective on the oncology office
Audio
Track 20 A mother’s experience with her daughter’s breast cancer
Audio
Track 21 Case discussion 6: Woman with prolonged response to trastuzumab
Audio
Track 22 Patient interview: Personal perspective on living with metastatic breast cancer
Audio
Track 23 Breast cancer as a chronic disease
Audio